Newron Pharmaceuticals S.p.A. header image

Newron Pharmaceuticals S.p.A.

NWRN

Equity

ISIN IT0004147952 / Valor 2791431

SIX Swiss Exchange (2026-05-06)
CHF 15.34-4.78%

Newron Pharmaceuticals S.p.A.
UMushroom community rating:

star star star star star
4.50 4 votes No rating yet
NegativeNeutralPositive

About company

Newron Pharmaceuticals S.p.A., established in 1999 and headquartered in Bresso, Italy, with a subsidiary in Morristown, New Jersey, is a biopharmaceutical company specializing in the development of innovative therapies for central and peripheral nervous system disorders. The company aims to expand its product portfolio through both internal research and development and strategic licensing and acquisition of novel compounds targeting the central nervous system (CNS) at various stages of development. Newron's shares are publicly traded on the SIX Swiss Exchange under the ticker symbol NWRN, as well as on the primary market of the Düsseldorf Stock Exchange and XETRA under the trading symbol NP5.

Summarized from source with an LLMView SourceSector: Healthcare

Latest Results ():

Summarized from source with an LLMView Source

Key figures

58.1%1Y
186%3Y
511%5Y

Performance

61.4%1Y
69.3%3Y
73.9%5Y

Volatility

Market cap

338 M

Market cap (USD)

Daily traded volume (Shares)

136,042

Daily traded volume (Shares)

1 day high/low

8.99 / 8.39

1 day high/low (USD)

52 weeks high/low

0.00 / 0.00

52 weeks high/low (USD)

Dividend ex-date

01 January, 2022

Dividend ex-date

Dividend

0.00

Dividend (USD)

Dividend yield (p.a.)

0.00%

Dividend yield (p.a.)

0.002022
0.002023
0.002024

Est dividend (USD)

0.00%2022
0.00%2023
0.00%2024

Est dividend yield

P/E ratio

10.00

P/E ratio

00.002022
00.002023
00.002024

Est P/E ratio

EPS

0.00

EPS (USD)

0.002022
0.002023
0.002024

Est EPS (USD)

Ratings & reviews

star star star star star

4.50

4 votes
Performance:
starstarstarstarstar
3.25
Innovation:
starstarstarstarstar
4.50
Society:
starstarstarstarstar
4.50
Nature:
starstarstarstarstar
3.75
Uwe K.
Switzerland, 30 Mar 2025
star star star star star
Könnte interessant sein.
Caterina F
Switzerland, 26 Mar 2025
star star star star star
Worth paying attention to
Markus Fässler
Switzerland, 05 Feb 2024
star star star star star
Evenamide, Newron’s innovative drug to treat schizophrenia, has proven safe and effective in use for TRS patients.

EQUITIES OF THE SAME SECTOR

Alnylam Pharmaceuticals Inc
Alnylam Pharmaceuticals Inc Alnylam Pharmaceuticals Inc Valor: 1806798
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
1.07%USD 301.11
BeiGene Ltd
BeiGene Ltd BeiGene Ltd Valor: 30165310
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.12%USD 297.49
Align Technology Inc
Align Technology Inc Align Technology Inc Valor: 1159441
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-1.84%USD 168.71
Icon PLC
Icon PLC Icon PLC Valor: 1017575
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
8.35%USD 121.32
Royalty Pharma PLC
Royalty Pharma PLC Royalty Pharma PLC Valor: 55041695
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.48%USD 50.44
Viatris Inc
Viatris Inc Viatris Inc Valor: 58198423
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
2.11%USD 15.52
Bristol-Myers Squibb Co
Bristol-Myers Squibb Co Bristol-Myers Squibb Co Valor: 914188
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-0.75%USD 56.95
Sareum Holdings PLC
Sareum Holdings PLC Sareum Holdings PLC Valor: 116566624
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.00%GBP 0.20
Venture Life Group PLC
Venture Life Group PLC Venture Life Group PLC Valor: 23084203
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.00%GBP 0.56
Alignment Healthcare Inc
Alignment Healthcare Inc Alignment Healthcare Inc Valor: 110387702
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-4.98%USD 18.30